<DOC>
	<DOC>NCT00044148</DOC>
	<brief_summary>The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.</brief_summary>
	<brief_title>The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Type 2 diabetes mellitus Greater than or equal to 30 years of age Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier. Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females B/P greater than 150 systolic and greater than 90 diastolic Hemoglobin Alc greater than 11% Liver Function Tests 2 times upper limit of normal Poor medical or psychiatric risk.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Persistent Albuminuria</keyword>
</DOC>